奥拉帕尼片致肝损伤1例

doi:10.19803/j.1672-8629.2019.12.12

中国药物警戒 ›› 2019, Vol. 16 ›› Issue (12): 762-764.
DOI: 10.19803/j.1672-8629.2019.12.12

奥拉帕尼片致肝损伤1例

徐银莹, 姜孙旻

南京医科大学附属无锡妇幼保健院,江苏无锡 214002

收稿日期:2019-12-18 修回日期:2019-12-18 出版日期:2019-12-15 发布日期:2019-12-18
通讯作者: *姜孙旻,女,硕士,主管药师,临床药学。
作者简介:徐银莹,女,本科,主管药师,临床药学。
基金资助:
无锡市卫计委科研青年项目（Q201603）：; 无锡市卫计委“科教强卫工程”青年医学人才项目（QNRC025）

One Case of Hepatic Dysfunction Induced by Olaparib Tablets

XU Yinying, JIANG Sunmin

The Affiliated Wuxi Maternity and Child Health Care Hospital of Nanjing Medical University, Wuxi Jiangsu 214002, China

Received:2019-12-18 Revised:2019-12-18 Online:2019-12-15 Published:2019-12-18

摘要/Abstract

中图分类号:

R994.11

徐银莹, 姜孙旻. 奥拉帕尼片致肝损伤1例[J]. 中国药物警戒, 2019, 16(12): 762-764.

XU Yinying, JIANG Sunmin. One Case of Hepatic Dysfunction Induced by Olaparib Tablets[J]. Chinese Journal of Pharmacovigilance, 2019, 16(12): 762-764.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.2019.12.12

https://zgywjj.magtechjournal.com/CN/Y2019/V16/I12/762

[1] 于乐成, 茅益民, 陈成伟. 药物性肝损伤诊治指南[J].中华肝脏病杂志, 2015, 23(10):1752-1769.
[2] 刘建平, 邢建民. 循证的药品不良反应评价方法[J]. 中国药物警戒, 2010, 7(1):12-15.
[3] Moore Kathleen, Colombo Nicoletta, Scambia Giovanni,et al.Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer[J]. N Engl J Med, 2018, 379(26):2495-2505.
[4] Friedlander Michael, Matulonis Ursula, Gourley Charlie,et al.Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy[J]. Br J Cancer,2018, 119(9):1075-1085.
[5] Moore K N, Monk B J.Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer[J]. Oncologist, 2016, 21(8):954-63.
[6] Pujadelauraine E, Ledermann J A, Selle F, et al.Olaparib tablets as maintenance therapy in patients with platinum-sensitive,relapsed ovarian cancer and a BRCA1/2 mutation(SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(9):1274-1284.
[7] Robson Mark, Im Seock-Ah, Senkus Elżbieta, et al.Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation[J]. N Engl J Med, 2017,377(6): 523-533.
[8] Bang Yung-Jue, Xu Rui-Hua, Chin Keisho, et al.Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(12):1637-1651.
[9] Ledermann Jonathan A, Harter Philipp, Gourley Charlie,et al.Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib main tenance monotherapy: an updated analysis from a randomised,placebo-controlled, double-blind, phase 2 trial[J]. Lancet Oncol, 2016, 17(11): 1579-1589.
[10] Oza Amit M, Cibula David, Benzaquen Ana Oaknin, et al.Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial[J]. Lancet Oncol, 2015, 16(1):87-97.
[11] Kaufman B, Shapirafrommer R, Schmutzler R K, et al.Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation[J]. J Clin Oncol,2015, 33(3):244-50.
[12] Domchek S M, Aghajanian C, Shapira-Frommer R, et al.Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy[J]. Gynecol Oncol,2016, 140(2):199-203.
[13] Liu J F, Barry W T, Birrer M, et al.Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study[J]. Lancet Oncol, 2014, 15(11):1207-1214.
[14] Del Conte G, Sessa C, Von Moos R, et al.Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours[J]. Br J Cancer, 2014, 111(4):651-659.
[15] Balmana J, Tung N M, Isakoff S J, et al.Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors[J]. Ann Oncol, 2014, 25(8):1656-1663.
[16] Choy Edwin, Butrynski James E, Harmon David C, et al.Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy[J].BMC Cancer, 2014, 14(1):1-6.
[17] Ledermann Jonathan, Harter Philipp, Gourley Charlie, et al.Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial[J]. Lancet Oncol, 2014, 15(8):852-861.
[18] Sandhu S K, Omlin A, Hylands L, et al.Poly (ADP-ribose)polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer[J]. Ann Oncol,2013, 24(5):1416-1418.
[19] Samol J, Ranson M, Scott E, et al.Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study[J].Invest New Drugs, 2012, 30(4):1493-1500.
[20] Ledermann J, Harter P, Gourley C, et al.Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer[J].N Engl J Med, 2012, 366(15):1382-1392.
[21] Kaye S B, Lubinski J, Matulonis U, et al.Phase II, open-label,randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor,and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer[J]. J Clin Oncol, 2012, 30(4):372-379.
[22] Khan O A, Gore M, Lorigan P, et al.A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436)and dacarbazine in patients with advanced solid tumours[J].Br J Cancer, 2011, 104(5):750-755.
[23] Liu J, Fleming G F, Tolaney S M, et al.A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer[J]. J Clin Oncol, 2011, 29(15):5028-5028.

奥拉帕尼片致肝损伤1例

One Case of Hepatic Dysfunction Induced by Olaparib Tablets

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李欣颖, 包蕾, 李舒冉, 赵荣华, 孙静, 谢丹, 鲍岩岩, 郭姗姗, 崔晓兰, 耿子涵. 疏风解毒胶囊对甲型流感病毒H1N1特异性抗体的影响[J]. 中国药物警戒, 2025, 22(8): 841-850.
[2]	王馨蔚, 彭一峰, 孙静, 冀祖恩, 包蕾, 罗恒磊, 耿子涵, 张虎娟, 李舒冉, 张敬升, 郭姗姗, 崔晓兰, 赵荣华. 一叶抗流感胶囊对人冠状病毒229E感染致小鼠肺炎的影响[J]. 中国药物警戒, 2025, 22(8): 851-855.
[3]	谢锐, 孙绮悦, 李艳英, 张敬升, 赵荣华, 郭姗姗, 耿子涵, 包蕾, 高双荣, 崔晓兰, 谢丹, 孙静. 双参苓颗粒对镉中毒致小鼠慢性肾功能衰竭模型的影响[J]. 中国药物警戒, 2025, 22(8): 856-862.
[4]	陈思颖, 丁雪丽, 刘淑佳, 张晓朦, 张冰, 林志健. 中草药心脏毒性预测模型研究[J]. 中国药物警戒, 2025, 22(8): 869-875.
[5]	蔡海丽, 张晓朦, 刘亚迪, 陈莉娟, 王雨, 张冰. 基于铁死亡探讨中药防治蒽环类药物心脏毒性的机制[J]. 中国药物警戒, 2025, 22(8): 876-882.
[6]	郑海云, 王志钢, 吴宏伟, 王少南, 王斌. 基于UPLC-Q-Exactive Orbitrap HRMS的补心安眠汤体内外化学成分分析[J]. 中国药物警戒, 2025, 22(8): 883-888.
[7]	孙雅, 王旭, 孙志, 周玉冰. 脓毒症伴急性肾损伤重症患者利奈唑胺剂量分析[J]. 中国药物警戒, 2025, 22(8): 889-895.
[8]	史琪, 王建新, 王桂杰, 陆悦阳, 主佳旭, 高蕊. 清气化痰丸治疗慢性阻塞性肺疾病急性加重的系统评价[J]. 中国药物警戒, 2025, 22(8): 914-919.
[9]	应婕, 徐霄龙, 李博, 刘腾文, 刘清泉. 金花清感颗粒治疗轻型流感临床应用的Meta分析[J]. 中国药物警戒, 2025, 22(8): 920-923.
[10]	柯秀琴, 海学武. 433例羟苯磺酸钙胶囊不良反应分析[J]. 中国药物警戒, 2025, 22(8): 924-927.
[11]	梁洁. 172例抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(8): 928-932.
[12]	刘疆, 陈洁, 邱思鸿, 李娜, 周莹, 陈永刚, 罗季. 基于美国FAERS数据库的奥马环素和莫西沙星不良事件分析[J]. 中国药物警戒, 2025, 22(8): 933-936.
[13]	赵牡丹, 朱明辉, 张欢, 赵远洋, 秦靖. 1例彭氏变形杆菌致糖尿病足感染的药学监护[J]. 中国药物警戒, 2025, 22(8): 937-940.
[14]	周玗洁, 黄晓婧, 陈明月, 杜鹏强, 王爱凤. 注射用头孢哌酮舒巴坦钠致重度血小板减少2例分析[J]. 中国药物警戒, 2025, 22(8): 941-943.
[15]	陈桦宝, 刘薇, 蒋婷, 郑玲利, 李静. 盐酸纳洛酮注射液致急性戒断综合征1例分析[J]. 中国药物警戒, 2025, 22(8): 944-946.